COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA) PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TNF TREATMENT IN TURKEY

被引：1
|
作者：
Ertenli, I [1 ]
机构：
[1] Hacettepe Univ, Fac Med, TR-06100 Ankara, Turkey
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1390
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A445 / A445
页数：1
相关论文
共 50 条
  • [1] Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
    Emery, Paul
    [J]. RHEUMATOLOGY, 2012, 51 : V22 - V30
  • [2] Cost-effectiveness of treatment strategies for rheumatoid arthritis patients with inadequate response to methotrexate
    Patel, VD
    Hay, J
    [J]. VALUE IN HEALTH, 2004, 7 (03) : 241 - 241
  • [3] Predicting response to anti-TNF treatment in rheumatoid arthritis patients
    Atzeni, Fabiola
    Antivalle, Marco
    Pallavicini, Francesca Bobbio
    Caporali, Roberto
    Bazzani, Chiara
    Gorla, Roberto
    Favalli, Ennio Giulio
    Marchesoni, Antonio
    Sarzi-Puttini, Piercarlo
    [J]. AUTOIMMUNITY REVIEWS, 2009, 8 (05) : 431 - 437
  • [4] Time to treatment response with abatacept in patients with RA and an inadequate response to Anti-TNF therapy
    Schiff, M.
    Dougados, M.
    Le Bars, M.
    Lafosse, C.
    Koncz, T.
    Genovese, M. C.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S307 - S308
  • [5] Cost-effectiveness simulation model of abatacept versus anti-TNF treatment strategies in rheumatoid arthritis in France
    Saraux, Alain
    Goupille, Philippe
    Gossec, Laure
    Bregman, Bruno
    Boccard, Eric
    Dupont, Danielle
    Beresmak, Ariel
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S463 - S463
  • [6] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Alex Diamantopoulos
    A. Finckh
    T. Huizinga
    D. K. Sungher
    L. Sawyer
    D. Neto
    F. Dejonckheere
    [J]. PharmacoEconomics, 2014, 32 : 775 - 787
  • [7] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Diamantopoulos, Alex
    Finckh, A.
    Huizinga, T.
    Sungher, D. K.
    Sawyer, L.
    Neto, D.
    Dejonckheere, F.
    [J]. PHARMACOECONOMICS, 2014, 32 (08) : 775 - 787
  • [8] COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN CHILE
    Elgart, J. F.
    Gonzalez, L.
    Aiello, E. C.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A223 - A223
  • [9] Anti-TNF Treatment in Rheumatoid Arthritis
    Geiler, Janina
    Buch, Maya
    McDermott, Michael F.
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (29) : 3141 - 3154
  • [10] Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
    Taylor, Peter C.
    Cerinic, Marco Matucci
    Alten, Rieke
    Avouac, Jerome
    Westhovens, Rene
    [J]. THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2022, 14
12345